Brief description not available

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed a technology that introduces vaccines that express macrophage-suppressing molecules to significantly enhance inflammatory T-cell functions for improved immune responses.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed isolated peptides that selectively bind M1 and M2 macrophages to enable precise diagnosis and targeted treatment of macrophage-associated diseases, including cancer.

Researchers at the University of California, Davis have developed an advancement in the field of healthcare technology, specifically in the development and application of silyl lipids for RNA vaccines.

Researchers at the University of California, Davis have developed a potential therapeutic strategy aiming at disrupting intercellular communication of pathogens using quorum sensing molecules and silicon-based pharmacophores.

Researchers at the University of California, Davis have developed a therapeutic use of cannabinoids for the treatment of Neurodegenerative Disorders (NDDs).

Researchers at the University of California, Davis have developed a nanoparticle system combining photothermal therapy and chemotherapy for enhanced cancer treatment.

Researchers at the University of California, Davis have developed non-invasive methods for intranasally delivering the drug allopregnanolone.

Researchers at the University of California, Davis and the Chiba University Center for Forensic Mental Health in Japan have collaborated to develop an enzyme inhibitor that prevents the onset of neurodevelopmental disorders.

Researchers at the University of California, Davis have developed a therapeutic approach to prevent and treat cancer cachexia by inhibiting soluble epoxide hydrolase, promoting resolution of systemic inflammation, mitigating muscle wasting, and improving survival outcomes in preclinical models without inducing toxicity or immunosuppression.

Researchers at the University of California, Davis have developed a technology that introduces an approach to creating semi-living, non-replicating cellular systems for advanced therapeutic applications.

Researchers at the University of California, Davis, have developed a method to prepare chemically well-defined HSA-drug conjugates, such that ligation can occur in vitro or in vivo under physiological condition.

Researchers at the University of California, Davis have developed a novel stem cell gene therapy approach utilizing a modified SYNGAP1 protein to treat Synaptic Ras GTPase Activating Protein 1-related intellectual disability (SRID).

Brief description not available

Brief description not available